156 related articles for article (PubMed ID: 38053418)
1. Review of the Developing Landscape of Prostate Biopsy and Its Roles in Prostate Cancer Diagnosis and Treatment.
Okubo Y; Sato S; Terao H; Yamamoto Y; Suzuki A; Hasegawa C; Yoshioka E; Ono K; Washimi K; Yokose T; Nakaigawa N; Kishida T; Miyagi Y
Arch Esp Urol; 2023 Nov; 76(9):633-642. PubMed ID: 38053418
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Accuracy of Prostate Biopsy for Detecting Cribriform Gleason Pattern 4 Carcinoma and Intraductal Carcinoma in Paired Radical Prostatectomy Specimens: Implications for Active Surveillance.
Ericson KJ; Wu SS; Lundy SD; Thomas LJ; Klein EA; McKenney JK
J Urol; 2020 Feb; 203(2):311-319. PubMed ID: 31483693
[TBL] [Abstract][Full Text] [Related]
3. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
[TBL] [Abstract][Full Text] [Related]
4. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy.
Tom MC; Nguyen JK; Lucianò R; Mian OY; Stephans KL; Ciezki JP; Smile TD; Wei W; McKenney JK; Magi-Galluzzi C; Tendulkar RD
J Urol; 2019 Oct; 202(4):710-716. PubMed ID: 31059665
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
Ma C; Downes M; Jain R; Ientilucci M; Fleshner N; Perlis N; van der Kwast T
Prostate; 2022 Feb; 82(3):345-351. PubMed ID: 34878188
[TBL] [Abstract][Full Text] [Related]
7. Comparative influence of cribriform growth and percent Gleason 4 in prostatic biopsies with Gleason 3+4 cancer.
Czaja RC; Tarima S; Wu R; Palagnmonthip W; Iczkowski KA
Ann Diagn Pathol; 2021 Jun; 52():151725. PubMed ID: 33610958
[TBL] [Abstract][Full Text] [Related]
8. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.
van Leenders GJLH; Kweldam CF; Hollemans E; Kümmerlin IP; Nieboer D; Verhoef EI; Remmers S; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ
Eur Urol; 2020 Feb; 77(2):191-198. PubMed ID: 31439369
[TBL] [Abstract][Full Text] [Related]
9. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.
Kweldam CF; Kümmerlin IP; Nieboer D; Steyerberg EW; Bangma CH; Incrocci L; van der Kwast TH; Roobol MJ; van Leenders GJ
Mod Pathol; 2017 Aug; 30(8):1126-1132. PubMed ID: 28530220
[TBL] [Abstract][Full Text] [Related]
10. Intraductal Adenocarcinoma of the Prostate With Cribriform or Papillary Ductal Morphology: Rare Biopsy Cases Lacking Associated Invasive High-grade Carcinoma.
Russell DH; Epstein JI
Am J Surg Pathol; 2022 Feb; 46(2):233-240. PubMed ID: 34619708
[TBL] [Abstract][Full Text] [Related]
11. The 2019 Genitourinary Pathology Society (GUPS) White Paper on Contemporary Grading of Prostate Cancer.
Epstein JI; Amin MB; Fine SW; Algaba F; Aron M; Baydar DE; Beltran AL; Brimo F; Cheville JC; Colecchia M; Comperat E; da Cunha IW; Delprado W; DeMarzo AM; Giannico GA; Gordetsky JB; Guo CC; Hansel DE; Hirsch MS; Huang J; Humphrey PA; Jimenez RE; Khani F; Kong Q; Kryvenko ON; Kunju LP; Lal P; Latour M; Lotan T; Maclean F; Magi-Galluzzi C; Mehra R; Menon S; Miyamoto H; Montironi R; Netto GJ; Nguyen JK; Osunkoya AO; Parwani A; Robinson BD; Rubin MA; Shah RB; So JS; Takahashi H; Tavora F; Tretiakova MS; True L; Wobker SE; Yang XJ; Zhou M; Zynger DL; Trpkov K
Arch Pathol Lab Med; 2021 Apr; 145(4):461-493. PubMed ID: 32589068
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity of multiparametric MRI and targeted biopsy for detection of adverse pathologies (Cribriform gleason pattern 4 and intraductal carcinoma): Correlation of detected and missed prostate cancer foci with whole mount histopathology.
Cai Q; Costa DN; Metter CK; Goldberg K; Roehrborn CG; Cadeddu J; Pedrosa I; Meng X; Mostardeiro TR; Shah RB
Urol Oncol; 2022 Oct; 40(10):452.e1-452.e8. PubMed ID: 36008255
[TBL] [Abstract][Full Text] [Related]
13. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
[TBL] [Abstract][Full Text] [Related]
14. Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.
Okubo Y; Sato S; Hasegawa C; Koizumi M; Suzuki T; Yamamoto Y; Yoshioka E; Ono K; Washimi K; Yokose T; Kishida T; Miyagi Y
Hum Pathol; 2023 May; 135():99-107. PubMed ID: 36738975
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma.
Montironi R; Cimadamore A; Gasparrini S; Mazzucchelli R; Santoni M; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M
Expert Rev Anticancer Ther; 2018 Jul; 18(7):685-693. PubMed ID: 29699428
[TBL] [Abstract][Full Text] [Related]
16. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
Rijstenberg LL; Hansum T; Kweldam CF; Kümmerlin IP; Remmers S; Roobol MJ; van Leenders GJLH
Histopathology; 2022 Jun; 80(7):1041-1049. PubMed ID: 35384019
[TBL] [Abstract][Full Text] [Related]
17. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.
Cohen RJ; Wheeler TM; Bonkhoff H; Rubin MA
Arch Pathol Lab Med; 2007 Jul; 131(7):1103-9. PubMed ID: 17616999
[TBL] [Abstract][Full Text] [Related]
18. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings.
Robinson BD; Epstein JI
J Urol; 2010 Oct; 184(4):1328-33. PubMed ID: 20723921
[TBL] [Abstract][Full Text] [Related]
19. Intraductal carcinoma of the prostate: a critical re-appraisal.
Varma M; Delahunt B; Egevad L; Samaratunga H; Kristiansen G
Virchows Arch; 2019 May; 474(5):525-534. PubMed ID: 30825003
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer outcomes of men with biopsy Gleason score 6 and 7 without cribriform or intraductal carcinoma.
Kweldam CF; Kümmerlin IP; Nieboer D; Verhoef EI; Steyerberg EW; Incrocci L; Bangma CH; van der Kwast TH; Roobol MJ; van Leenders GJ
Eur J Cancer; 2016 Oct; 66():26-33. PubMed ID: 27522247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
